Table 4.
ESR1 mutation and endocrine therapy immediately before or after testing (n=13)
| Patients and GAs | Pretest endocrine therapy | Response |
|---|---|---|
| #2 D538G +2 GAs | Exemestane + everolimus | SD for 6 months |
| #3 L536_D538>P +5 GAs | Exemestane + everolimus | SD for 8 months |
| #4 Y537C +8 GAs | Fulvestrant | SD for 8 months |
| #5 D538G +3 GAs | Exemestane + everolimus | SD for 12 months |
| #8 Y537N +7 GAs | Fulvestrant | PD |
| #10 Y537S +1 GA | Tamoxifen | PD |
| #12 Y537S +4 GA | Fulvestrant | PD |
|
| ||
| Patients and GAs | Post-test endocrine therapy | Response |
|
| ||
| #17 Y537S +8 GAs | Exemestane + everolimus | PD |
| #21 Y537S +3 GAs | Exemestane + everolimus | PD |
| #22 D538G +4 GAs | Exemestane + everolimus | SD for 18 months |
| #23 D538G +4 GAs | Exemestane + everolimus | SD for 6 months |
| #30 Y537S +2 GAs | Fulvestrant | PD |
| #31 D538G +0 GA | Fulvestrant | PD |
Abbreviations: GA, genomic alteration; PD, progression of disease; SD, stable disease.